{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:19:22Z","timestamp":1791001162965,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T00:00:00Z","timestamp":1496707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s40265-017-0771-8","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T06:19:46Z","timestamp":1496729986000},"page":"1247-1249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Cerliponase Alfa: First Global Approval"],"prefix":"10.1007","volume":"77","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"771_CR1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pediatrneurol.2017.01.034","volume":"69","author":"RE Williams","year":"2017","unstructured":"Williams RE, Adams HR, Blohm M, et al. Management strategies for CLN2 disease. Pediatr Neurol. 2017;69:102\u201312.","journal-title":"Pediatr Neurol."},{"key":"771_CR2","unstructured":"BioMarin Pharmaceutical. BRINEURA (cerliponase alfa): US prescribing information. 2017. \n                        http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761052lbl.pdf\n                        \n                    . Accessed 5 May 2017."},{"key":"771_CR3","unstructured":"Eurpean Medicines Agency. Cerliponase alfa (Brineura): summary of product characteristics 2017. \n                        http:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170530137963\/anx_137963_en.pdf\n                        \n                    . Accessed 2 June 2017."},{"issue":"Suppl 1","key":"771_CR4","first-page":"7","volume":"59","author":"P Gissen","year":"2017","unstructured":"Gissen P, Schulz A, Specchio N, et al. Intracerebroventricular cerliponase alfa (BMN 190) in children with CLN2 disease: results from a phase 1\/2, open-label, dose-escalation study (abstract). Dev Med Child Neurol. 2017;59(Suppl 1):7\u20138.","journal-title":"Dev Med Child Neurol."},{"issue":"1\u20132","key":"771_CR5","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.ymgme.2016.11.311","volume":"120","author":"A Schulz","year":"2017","unstructured":"Schulz A, Specchio N, Gissen P, et al. Long-term safety and efficacy of intracerebroventricular enzyme replacement therapy with cerliponase alfa in children with CLN2 disease: interim results from an ongoing multicenter, multinational extension study (abstract no. 302). Mol Genet Metab. 2017;120(1\u20132):S120.","journal-title":"Mol Genet Metab."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0771-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0771-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T05:32:14Z","timestamp":1499405534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0771-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0771-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]}}}